A heart valve dedicated for aortic regurgitation: Review of technology and early clinical experience with the transfemoral Trilogy system.
Andreas BaumbachKush P PatelSimon KennonMick OzkorAnthony MathurFrank de la HuertaAlexander R TammPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2023)
Aortic regurgitation (AR) is associated with morbidity and premature mortality. Surgical aortic valve replacement is not an option for many patients due to an adverse surgical risk profile, whilst transcatheter aortic valve implantation with most available prostheses has demonstrated suboptimal implantation success and outcomes. The JenaValve Trilogy™ system provides an attractive solution for such patients as it utilizes clips that directly attach onto the native valve leaflets to anchor. Initially designed for transapical delivery, the current transfemoral delivery system is under investigation in the United States and approved for aortic stenosis and regurgitation in Europe. We present an expert review on the technical aspects of the Trilogy system, provide a guide for implantation, discuss the available evidence for the technology and provide illustrative case examples.
Keyphrases
- aortic stenosis
- transcatheter aortic valve implantation
- aortic valve replacement
- aortic valve
- ejection fraction
- transcatheter aortic valve replacement
- left ventricular
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- heart failure
- coronary artery disease
- atrial fibrillation
- mitral valve
- risk factors
- prognostic factors
- patient reported outcomes
- pulmonary arterial hypertension
- cardiovascular events